[Tendency and prospect of the development of new ARBs].
The AT1 receptor blocker(ARB) has differential pharmacological merits from the ACE inhibitor, and is expected to be the promising agent for treatment of various cardiovascular diseases such as heart failure and nephropathy, as well as hypertension. Three ARBs, losartan potassium, candesartan cilexetil and valsartan, have been already clinically used in Japan. In the near future, several new ARBs, including telmisartan, ormethartan and irbesartan, are expected to become available for clinical use. In this review, pharmacological properties and future view of each ARB are described and discussed.
Kim
Shokei
S
Department of Pharmacology, Osaka City University Medical School.
D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine; D019808:Losartan; C077793:candesartan cilexetil